Voyager Therapeutics, Inc. (VYGR) News
Follow Voyager Therapeutics, Inc. (VYGR) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 8 public stories across 6 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
Voyager Therapeutics Q3'26 Earnings Preview: EPS Estimated at (0.42) USD
Voyager Therapeutics is set to report Q3'26 results on November 10; revenue is estimated at $6.35 million and EPS at (0.42) USD. The release time is unspecified.
EQUITY | Nov 09, 2026, 12:01 PM UTC
L
Voyager Therapeutics 3Q Loss/Shr 40c >VYGR
Voyager Therapeutics 3Q Loss/Shr 40c >VYGR
EQUITY | Nov 05, 2026, 09:12 PM UTC
L
BRIEF-Voyager Therapeutics Q3 Operating Income USD -26.422 Million
Nov 05 (Reuters) - Voyager Therapeutics Q3 net income USD -24.694 million.
EARNINGS | Nov 05, 2026, 09:04 PM UTC
L
VYGR: Tau-targeting therapies and novel delivery platforms advance toward key clinical and partnership milestones
Three major catalysts this year include tau-targeting therapies, capsid proof-of-concept, and NeuroShuttle platform progress. Key tau antibody and gene therapy programs are advancing toward clinical milestones, with part
EQUITY | Sep 08, 2026, 08:46 PM UTC
L
Voyager Therapeutics to present at upcoming investor conferences
Voyager Therapeutics said it will participate in upcoming investor conferences, with a webcast available for the Wel… conference.
EQUITY | Sep 01, 2026, 12:07 PM UTC
L
VYGR - Voyager to Present at Upcoming Investor Conferences
VYGR - Voyager to Present at Upcoming Investor Conferences
EQUITY | Sep 01, 2026, 12:01 PM UTC
L
VYGR Additional VY1706 (Alzheimer's anti-tau Gene therapy) preclinical data bode well for program/company; reiterate BUY, $12PT @ Canaccord
VYGR Additional VY1706 (Alzheimer's anti-tau Gene therapy) preclinical data bode well for program/company; reiterate BUY, $12PT @ Canaccord
EQUITY | Jul 14, 2026, 12:18 PM UTC
H
Jim Cramer: TE Connectivity Is ‘Terrific,’ Buy This Industrial Stock
On CNBC’s “ Mad Money Lightning Round,” Jim Cramer recommended buying GE Vernova Inc. (NYSE: GEV ), adding that the Charitable Trust has a very big position in the stock. Lending support to his choice, Bernstein analyst
RATES | Jul 01, 2026, 11:49 AM UTC